Medacta presented new data that showed the success of its orthopedic product line following the 8th M.O.R.E. International Symposium, a clinical educational meeting featuring more than 1,000 surgeons from around the globe.
During the meeting in Switzerland, Richard Field, MD, orthopedic surgery professor at St. George's University of London, United Kingdoms, presented clinical results on Medacta's AMIStem hip implant study. The 421-patient study complied with the UK Orthopaedic Data Evaluation Panel recommendation, which evaluates an implant's performance and gives surgeons factors to consider when choosing implants for joint replacement procedures.
Here are six key notes:
1. The study found AMIStem implants' five-year survival rate was 97.75 percent.
2. The implant received a 5A ODEP rating, which places the implant on the right path to obtaining a 10A rating, which requires a 10-year follow-up.
3. Medacta says the implant is deemed safe and reliable for cement-less total hip arthroplasty based on these findings.
4. The findings also illustrate AMIS achieved good medium-term results for implant survival and clinical outcomes evaluations.
5. Surgeons have used the AMIStem more than 100,000 times to date, with surgeons utilizing the AMIS technique more than 200,000 times.
6. Medacta manufactures orthopedic implants, neurosurgical systems and instrumentation.
"The high adoption rate of Medacta's surgical products and promising clinical data reviewed at the M.O.R.E. Symposium are testaments to the work we're doing to improve the orthopedic experience both for patients and surgeons," said Francesco Siccardi, executive vice president, Medacta. "The positive feedback we've received for AMIStem and continued enthusiasm for GMK Sphere, MyKnee and MySpine suggest there is a clear need for products that combine meticulous design, responsible innovation and a commitment to health-economic sustainability."